Related Experiment Video
Updated: Feb 10, 2026

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
Published on: January 9, 2020
Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers
Panagiota Economopoulou1, Ioannis Kotsantis2, Amanda Psyrri3
1Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, School of Medicine, 1St Rimini St, 12462, Haidari, Athens, Greece. panagiota_oiko@hotmail.com.
Opinion Statement:
The discovery and antibody targeting of immune regulatory molecules such as programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) pathways have led to clinically meaningful anti-cancer results. Rapid advances are being made in a variety of tumor types resulting in regulatory approvals in melanoma, non small cell lung cancer, and renal cell cancer. Numerous ongoing studies are expected to establish the worth of PD-1 pathway inhibitors in other tumor types as well as in combinations with approved agents. Head and neck squamous cell carcinoma (HNSCC) represents a complex group of malignancies characterized by profound immunosuppression and is an excellent candidate for investigation in this exciting field. However, given the fact that a subset of patients will likely benefit, it is critical to focus on biomarker development for appropriate patient selection and facilitation of trial design. As immunotherapy is settling in cancer treatment, immune checkpoint inhibitors are emerging as one of the most promising agents.
Insights
Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) show promise in cancer treatment. Biomarker development is crucial for selecting head and neck squamous cell carcinoma patients who will benefit from these therapies.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Immune checkpoint inhibitors targeting PD-1 and CTLA-4 pathways have yielded significant anti-cancer outcomes.
- Approvals in melanoma, non-small cell lung cancer, and renal cell cancer highlight their clinical efficacy.
- Ongoing research explores PD-1 inhibitors in diverse tumor types and combination therapies.
Purpose of the Study:
- To evaluate the potential of PD-1 pathway inhibitors in treating head and neck squamous cell carcinoma (HNSCC).
- To emphasize the critical need for biomarker development in HNSCC for patient selection and trial design.
Main Methods:
- Review of current clinical data and research on immune checkpoint inhibitors.
- Analysis of HNSCC characteristics, including its immunosuppressive nature.
- Discussion of biomarker strategies for patient stratification.
Main Results:
- PD-1 and CTLA-4 pathway inhibition demonstrates clinical success in various cancers.
- HNSCC presents a promising, yet challenging, area for immunotherapy investigation due to profound immunosuppression.
- Biomarker-driven patient selection is essential for maximizing therapeutic benefit.
Conclusions:
- Immune checkpoint inhibitors are a rapidly advancing frontier in cancer treatment.
- Targeting PD-1 pathways in HNSCC warrants further investigation, with a focus on identifying responsive patient subsets.
- Biomarker development is paramount for the successful clinical application of immunotherapy in HNSCC.
Related Concept Videos
Arteries of the Head and Neck
The internal carotid arteries supply blood to the anterior portion of the cerebrum. They enter the...
Veins of Head and Neck
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Thermodynamics: Chemical Potential and Activity
The thermodynamic equilibrium constant is more accurately defined in terms of activity rather than concentration.
Muscles of the Anterior Neck

